Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer

Jung Rae Cho1,*, Keun-Wook Lee2,*, Heung-Kwon Oh1, Jin Won Kim2, Ji-Won Kim2, Duck-Woo Kim1, Jee Hyun Kim2, Sung-Bum Kang1

1Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
2Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

INTRODUCTION

Colorectal cancer is the third most common type of cancer worldwide and in Korea [1,2]. Surgical resection with curative intent is the mainstay of treatment for patients with locoregional colon cancer. For stage III colon cancer, the benefit of adjuvant chemotherapy following curative resection is well-established [3-5]. However, the effectiveness of adjuvant...
chemotherapy for stage II colon cancer has not been clearly proven, and the expected absolute survival benefit of adjuvant treatment is in the range of 2\%–5\% at best [4-7].

According to previous large-scaled phase III trials and current clinical guidelines, including the National Comprehensive Cancer Network (NCCN), the addition of oxaliplatin to 5-fluorouracil (5-FU)/leucovorin in adjuvant chemotherapy following resection of stage II colon cancer has not been demonstrated, even in the cases with high-risk factors such as pathologic T4 lesion or bowel perforation [4,7]. However, oxaliplatin can induce cumulative dose-dependent grade 3 or 4 neurotoxicity in about 8\%–12\% of patients, and this neurotoxicity lasts for 4 years in 15.5\% of patients, especially those older than 70 years [8,9]. Chemotherapy-induced peripheral sensory neuropathy is associated with a poor quality of life [10].

Patients with colon cancer prefer oral chemotherapy over intravenous (IV) administration if the drug efficacy is not compromised [11]. In stage III colon cancer, oral capecitabine achieved similar survival outcomes but significantly fewer adverse events than IV 5-FU plus leucovorin [12]. However, the efficacy of oral fluoropyrimidine monotherapy as adjuvant chemotherapy in stage II colon cancer has not been widely investigated. Therefore, in this study, we compared the effectiveness of adjuvant oral fluoropyrimidine monotherapy with IV fluoropyrimidine-based chemotherapy for high-risk stage II colon cancer.

**METHODS**

**Ethical statement**

The Institutional Review Board at Seoul National University Bundang Hospital approved this retrospective study before the commencement of data collection and analysis, and the requirement for informed consent was waived (No. B-1905-540-102).

**Patients and treatments**

This single-institution, retrospective, observational study included patients who underwent curative-intent resection for histologically proven stage II colonic adenocarcinoma with high-risk features at Seoul National University Bundang Hospital in Seongnam, Korea between 2003 and 2014. All data were retrospectively extracted from an electronic medical record. The data items included patient demographics such as age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) physical status (PS) classification, tumor location (right-sided, ascending to the transverse colon; left-sided, splenic flexure to the sigmoid colon), and microsatellite instability (MSI) status. Patients with high-risk stage II colon cancer had at least one of the following features: poorly differentiated histology, lymphatic invasion, venous invasion, perineural invasion, harvested lymph node less than 12, bowel obstruction, tumor perforation, or pathologic T4 lesion. Patients with high MSI were excluded as they have a better prognosis and gain little benefit from adjuvant therapy based on the guidelines by NCCN and the European Society for Medical Oncology (ESMO) [7,19].

After resection of colon cancer, patients were classified into 3 groups according to their postoperative management: (1) observation group; (2) oral fluoropyrimidine monotherapy group, such as capecitabine (starting dose of 1,250 mg/m<sup>2</sup> twice daily for 14 days repeated every 21 days for 8 cycles) or tegafur/uracil (UFT; administered at a dose of 300 mg/m<sup>2</sup> daily for 5 cycles, each cycle comprising 4 weeks of oral chemotherapy administration followed by 1-week rest period); and (3) IV fluoropyrimidine-based chemotherapy group, including fluorouracil plus leucovorin (FL; 5-FU 400 mg/m<sup>2</sup> plus leucovorin 20 mg/m<sup>2</sup> daily for 5 days repeated every 28 days for 6 cycles) or FL with oxaliplatin (FOLFOX; oxaliplatin 85 mg/m<sup>2</sup> on day 1, leucovorin 400 mg/m<sup>2</sup> on day 1, 5-FU bolus 400 mg/m<sup>2</sup> on day 1 followed by 2,400 mg/m<sup>2</sup> for 46 hours, repeated every 2 weeks for 12 cycles) [7,12,14-16]. The choice of adjuvant chemotherapy regimen and dosage modification during the chemotherapy period was determined by experienced medical oncologists.

**Outcome measures**

To compare the effectiveness of postoperative management for each group, long-term oncologic outcomes such as 5-year overall survival (OS) and disease-free survival (DFS) were analyzed. OS was defined as the time between operation date and death from any cause or the date when the patient was last confirmed to be alive. DFS was defined as the time between the date of operation and first relapse, the occurrence of a second primary colorectal cancer, death from any cause, or the last date when the patient was confirmed to be disease-free [17]. All adverse events during chemotherapy were evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 of the National Cancer Institute [18], and the most severe grade in each event category was considered the representative one. In addition, the number of patients with dose-reduced chemotherapy due to chemotherapy-induced toxicity and the rate of chemotherapy discontinuation were assessed.

**Statistical analysis**

One-way analysis of variance or independent-samples t-tests were performed to compare continuous variables, and the chi-square tests were used to compare categorical data. Continuous data are expressed as mean with standard deviation, and categorical variables are expressed as the number with the percentage. The probabilities of OS and DFS were estimated using the Kaplan-Meier method and compared using log-
rank tests. Multivariate analyses with the Cox regression hazard model were conducted to identify the factors that were independently associated with survival. A stepwise backward elimination technique, including variables initially with a P-value less than 0.1 in the univariate analysis, was used. All statistical tests were 2-sided, and P-values of <0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics ver. 22 (IBM Corp., Armonk, NY, USA).

RESULTS

Patients and treatments

Among 706 patients with pathologic stage II colon cancer at our institution from 2003 to 2014, 350 patients were excluded from analysis due to high MSI status, no high-risk features, or follow-up loss after surgical resection. Finally, 356 patients were included in the analysis. They were classified into 3 groups according to their postoperative management: 87 patients (24.4%) in the observation group, 172 (48.3%) in the oral fluoropyrimidine monotherapy group, and 97 (27.2%) in the IV fluoropyrimidine-based chemotherapy group. The

**Table 1.** Baseline characteristics according to postoperative treatment groups (n = 356)

| Characteristic               | Observation | OG          | IVG          | P-value | P-value, OG vs. IVG |
|-----------------------------|-------------|-------------|-------------|---------|---------------------|
| No. of patients             | 87 (24.4%)  | 172 (48.3%) | 97 (27.2%)  | <0.001<sup>a</sup> | <0.001<sup>b</sup> |
| Age (yr)                    | 74.5 ± 11.1 | 63.8 ± 10.7 | 56.5 ± 10.8 | <0.001<sup>a</sup> | 0.742<sup>c</sup> |
| Female sex                  | 32 (36.8%)  | 67 (39.0%)  | 41 (42.3%)  | 0.119<sup>c</sup> | 0.607<sup>c</sup> |
| Body mass index (kg/m<sup>2</sup>) | 22.5 ± 3.6 | 23.4 ± 3.2 | 22.7 ± 3.2 | 0.082<sup>a</sup> | 0.095<sup>b</sup> |
| ASA PS grade                |             |             |             |         |                     |
| I, II                       | 63 (72.4%)  | 163 (94.8%) | 94 (96.9%)  | <0.001<sup>c</sup> | 0.546<sup>c</sup> |
| III–V                       | 24 (27.6%)  | 9 (5.2%)    | 3 (3.1%)    |         |                     |
| Tumor location<sup>d</sup>  |             |             |             |         |                     |
| Right-sided                 | 38 (43.7%)  | 47 (27.3%)  | 32 (33.0%)  |         |                     |
| Left-sided                  | 49 (56.3%)  | 125 (72.7%) | 65 (67.0%)  |         |                     |
| Operative method            |             |             |             |         |                     |
| Open<sup>e</sup>           | 41 (47.1%)  | 45 (26.2%)  | 39 (40.2%)  |         |                     |
| Laparoscopy                 | 46 (52.9%)  | 127 (73.8%) | 58 (59.8%)  |         |                     |
| Harvested LNs               | 42.5 ± 19.9 | 41.7 ± 20.2 | 47.9 ± 22.9 |         |                     |
| Emergency                   |             |             |             |         |                     |
| No                          | 79 (90.8%)  | 157 (91.3%) | 86 (88.7%)  | 0.775<sup>c</sup> | 0.522<sup>c</sup> |
| Yes                         | 8 (9.2%)    | 15 (8.7%)   | 11 (11.3%)  |         |                     |

Values are presented as number (%) or mean ± standard deviation.
OG, oral fluoropyrimidine monotherapy group; IV, intravenous fluoropyrimidine-based chemotherapy group; ASA, American Society of Anesthesiologists; PS, physical status; LNs, lymph nodes.

<sup>a</sup>One-way analysis of variance; <sup>b</sup>independent 2 samples t-test; <sup>c</sup>chi-square test. <sup>d</sup>Tumor location is divided into right-sided (ascending to transverse colon) and left-sided (splenic flexure to the sigmoid colon). <sup>e</sup>Conversion to open surgery during laparoscopy was included.
oral fluoropyrimidine monotherapy group was subdivided into those receiving capecitabine (n = 110, 64.0%) and those receiving UFT (n = 62, 36.0%). The IV fluoropyrimidine-based chemotherapy group was subdivided into FL (n = 22, 22.7%) and FOLFOX (n = 75, 77.3%) (Fig. 1).

According to the baseline characteristics, the observation group had the highest mean age (74.5 ± 11.1 years) (Table 1). The mean age of the oral fluoropyrimidine monotherapy group was higher than that of the IV chemotherapy group (63.8 ± 10.7 vs. 56.5 ± 10.8, P < 0.001). The proportion of ASA PS classification III or IV was higher, and right-sided tumor location was more common in the observation group than in the adjuvant chemotherapy groups, but similar between the oral fluoropyrimidine monotherapy group and the IV chemotherapy group. The number of harvested lymph nodes was not significantly different among the 3 groups.

Table 2 shows the high-risk features of stage II colon cancer according to the treatment groups. The proportion of pathologic T4 lesions was higher in the IV chemotherapy group than in the other groups (P < 0.001). The IV chemotherapy group had more multiple high-risk features than the other groups.

Survival outcomes

The median follow-up time was 47.7 months (range, 2–133 months). The 5-year OS and DFS rates of all patients were 85.5% and 78.0%, respectively. The 5-year OS rate was 62.9% for the observation group, 91.2% for the oral fluoropyrimidine monotherapy group, and 92.6% for the IV fluoropyrimidine-based chemotherapy group (log-rank, P < 0.001). The 5-year DFS rates for patients in the observation, oral fluoropyrimidine monotherapy, and IV chemotherapy groups were 57.2%, 85.1%, and 81.9%, respectively (log-rank, P < 0.001) (Fig. 2). Between the oral fluoropyrimidine monotherapy group and the IV chemotherapy group, the 5-year OS and DFS rates were not different (log-rank, P = 0.090 and P = 0.535, respectively). In multivariate analysis, age over 70 years and no adjuvant

---

**Table 2. High-risk pathology of stage II colon cancer according to postoperative treatment groups**

| Variable                  | Observation (n = 87) | OG (n = 172) | IVG (n = 97) | P-value | P-value, OG vs. IVG |
|---------------------------|---------------------|-------------|-------------|---------|-------------------|
| T4 lesion                 | 10 (11.5)           | 22 (12.8)   | 34 (35.1)   | <0.001  | <0.001            |
| Poorly differentiated     | 7 (8.0)             | 4 (2.3)     | 7 (7.2)     | 0.073   | 0.061             |
| Lymphatic invasion        | 22 (25.3)           | 55 (32.0)   | 34 (35.1)   | 0.344   | 0.686             |
| Venous invasion           | 8 (9.2)             | 11 (6.4)    | 13 (13.4)   | 0.155   | 0.073             |
| Perineural invasion       | 28 (32.2)           | 71 (41.3)   | 45 (46.4)   | 0.140   | 0.443             |
| Harvested LNs <12         | 1 (1.1)             | 3 (1.7)     | 1 (1.0)     | 0.869   | 0.999             |
| Bowel obstruction         | 33 (37.9)           | 52 (30.2)   | 27 (27.8)   | 0.301   | 0.781             |
| Tumor perforation         | 17 (19.5)           | 27 (15.7)   | 11 (11.3)   | 0.305   | 0.366             |
| No. of high-risk features | 1                   | 60 (69.0)   | 119 (69.2)  | 46 (47.4)| 0.001             |
|                          | ≥2                   | 27 (31.0)   | 53 (30.8)   | 51 (52.6)| 0.001             |

Values are presented as number (%).
OG, oral fluoropyrimidine monotherapy group; IVG, intravenous fluoropyrimidine-based chemotherapy group; LNs, lymph nodes.

---

**Fig. 2.** Analysis of survival (Kaplan-Meier) according to the postoperative management for high-risk stage II colon cancer. (A) Overall survival (OS) and (B) disease-free survival (DFS). IV, intravenous.
Table 3. Univariate and multivariate hazard ratio for overall survival and disease-free survival

| Variable                          | Overall survival |              |              | Disease-free survival |              |              |
|-----------------------------------|------------------|--------------|--------------|-----------------------|--------------|--------------|
|                                   | Univariate       | Multivariate | P-value      | Univariate            | Multivariate | P-value      |
| Age (yr)                          |                  |              |              |                       |              |              |
| <70                               | -                | 5.019 (2.935–8.582) | <0.001       | 2.229 (1.132–4.391)   | 0.020        |
| ≥70                               | -                | 2.976 (1.917–4.620) | <0.001       | 1.773 (1.023–3.072)   | 0.041        |
| Sex                               |                  |              |              |                       |              |              |
| Male                              | -                | 1.333 (0.773–2.296) | 0.301        | -                     |              |              |
| Female                            | -                | 0.661 (0.413–1.056) | 0.083        | 0.705 (0.440–1.129)   | 0.146        |
| Body mass index (kg/m²)           |                  |              |              |                       |              |              |
| <25                               | -                | 1.180 (0.670–2.078) | 0.566        | -                     |              |              |
| ≥25                               | -                | 1.192 (0.736–1.931) | 0.476        | -                     |              |              |
| Tumor location*                   |                  |              |              |                       |              |              |
| Right-sided                       | -                | 0.966 (0.554–1.683) | 0.902        | -                     |              |              |
| Left-sided                        | -                | 1.123 (0.697–1.808) | 0.634        | -                     |              |              |
| Differentiation                   |                  |              |              |                       |              |              |
| Well to moderate                  | -                | 2.134 (0.768–5.932) | 0.146        | -                     |              |              |
| Poor                              | -                | 1.612 (0.650–3.998) | 0.303        | -                     |              |              |
| T stage                           |                  |              |              |                       |              |              |
| T3                                | -                | 1.209 (0.654–2.236) | 0.545        | -                     |              |              |
| T4                                | -                | 1.505 (0.917–2.471) | 0.106        | -                     |              |              |
| Perforation                       |                  |              |              |                       |              |              |
| Absent                            | -                | 0.646 (0.258–1.618) | 0.351        | -                     |              |              |
| Present                           | -                | 0.594 (0.273–1.291) | 0.188        | -                     |              |              |
| Obstruction                       |                  |              |              |                       |              |              |
| Absent                            | -                | 1.716 (1.031–2.855) | 0.038        | 1.292 (0.763–2.188)   | 0.341        | 1.389 (0.895–2.154) | 0.143 |
| Present                           | -                | 1.209 (0.654–2.236) | 0.545        | 1.505 (0.917–2.471)   | 0.106        | 1.895 (1.357–2.634) | 0.003 |
| Adjuvant chemotherapy             |                  |              |              |                       |              |              |
| Observation                       |                  |              |              |                       |              |              |
| OG                                | -                | 0.190 (0.106–0.342) | <0.001       | 0.306 (0.156–0.603)   | 0.001        | 0.284 (0.173–0.468) | <0.001 |
| IVG without oxaliplatin           | -                | 0.038 (0.009–0.167) | <0.001       | 0.078 (0.016–0.385)   | 0.002        | 0.120 (0.038–0.378) | <0.001 |
| IVG with oxaliplatin              | -                | 0.156 (0.064–0.375) | <0.001       | 0.302 (0.109–0.833)   | 0.021        | 0.310 (0.164–0.587) | <0.001 |

Median follow-up time was 47.7 months.

HR, hazard ratio; CI, confidence interval; OG, oral fluoropyrimidine monotherapy group; IVG, intravenous fluoropyrimidine-based chemotherapy group.

* Tumor location is divided into right-sided (ascending to transverse colon) and left-sided (descending to the sigmoid colon).
chemotherapy were associated with poor OS and DFS (Table 3).

**Adverse events of adjuvant chemotherapy**

The incidence of adverse events was different between the oral fluoropyrimidine monotherapy and the IV chemotherapy groups (69.8% vs. 99.0%, \( P < 0.001 \)). Adverse events except hand-foot syndrome were more frequent in the IV chemotherapy group than in the oral fluoropyrimidine monotherapy group. Severe adverse events of grade \( \geq 3 \) were more frequent in the IV chemotherapy group than in the oral fluoropyrimidine monotherapy group (Table 4).

Chemotherapy discontinuation rates were comparable between the oral fluoropyrimidine agent and IV chemotherapy groups (9.9% vs. 10.3%, \( P = 0.911 \)). The number of cases requiring dose reduction during chemotherapy due to toxicity was lower in the oral fluoropyrimidine agent group than in the IV chemotherapy group (15.7% vs. 58.8%, \( P < 0.001 \)).

**Table 4. Adverse events during adjuvant chemotherapy**

| Variable         | OG (n = 172) | IVG (n = 97) | P-value  |
|------------------|--------------|--------------|----------|
| Overall          | 120 (69.8)   | 96 (99.0)    | <0.001   |
| Neutropenia      | 5 (2.9)      | 35 (36.1)    | <0.001   |
| Diarrhea         | 30 (17.4)    | 30 (30.9)    | 0.011    |
| Nausea/vomiting  | 52 (30.2)    | 71 (73.2)    | <0.001   |
| Hand-foot syndrome | 79 (45.9)  | 4 (4.1)      | <0.001   |
| Stomatitis       | 22 (12.8)    | 30 (30.9)    | <0.001   |
| Neutropathy      | 1 (0.6)      | 62 (63.9)    | <0.001   |
| CTCAE grade \( \geq 3 \) | 21 (12.2) | 33 (34.0)    | <0.001   |
| Neutropenia      | 2 (1.2)      | 19 (19.6)    | <0.001   |
| Diarrhea         | 7 (4.1)      | 6 (6.2)      | 0.437    |
| Nausea/vomiting  | 1 (0.6)      | 8 (8.2)      | 0.006    |
| Hand-foot syndrome | 13 (7.6)  | 0 (0)        | 0.267    |
| Stomatitis       | 1 (0.6)      | 2 (2.1)      | 0.007    |
| Neutropathy      | 0 (0)        | 4 (4.1)      | 0.007    |

Values are presented as number (%).

OG, oral fluoropyrimidine monotherapy group; IVG, intravenous fluoropyrimidine-based chemotherapy group; CTCAE, Common Terminology Criteria for Adverse Events.

**Table 5. Baseline characteristics according to administration of oxaliplatin**

| Characteristic          | Without oxaliplatin (n = 194) | With oxaliplatin (n = 75) | P-value |
|-------------------------|--------------------------------|--------------------------|---------|
| Age (yr)                | 62.7 ± 11.2                     | 57.3 ± 10.5              | <0.001  |
| Female sex              | 75 (38.7)                      | 33 (44.0)                | 0.423   |
| Body mass index (kg/m²) | 23.3 ± 3.2                     | 22.7 ± 3.3               | 0.160   |
| ASA PS grade            |                                |                          |         |
| I, II                   | 184 (94.8)                     | 73 (97.3)                | 0.375   |
| III–V                   | 10 (5.2)                       | 2 (2.7)                  |         |
| Tumor location          |                                |                          |         |
| Right-sided             | 50 (25.8)                      | 29 (38.7)                | 0.037   |
| Left-sided              | 144 (74.2)                     | 46 (61.3)                |         |
| Operative method        |                                |                          |         |
| Open                    | 58 (29.9)                      | 26 (34.7)                | 0.449   |
| Laparoscopy              | 136 (70.1)                     | 49 (65.3)                |         |
| Harvested LNs           | 41.6 ± 20.3                    | 50.0 ± 23.0              | 0.004   |
| Emergency               |                                |                          |         |
| No                      | 177 (91.2)                     | 66 (88.0)                | 0.420   |
| Yes                     | 17 (8.8)                       | 9 (12.0)                 |         |

Values are presented as mean ± standard deviation or number (%).

ASA, American Society of Anesthesiologists; PS, physical status; LNs, lymph nodes.

\(^{a}\) Independent 2 samples t-tests; \(^{b}\) chi-square test. \(^{c}\) Tumor location is divided into right-sided (ascending to transverse colon) and left-sided (descending to the sigmoid colon). \(^{d}\) Conversion to open surgery during laparoscopy was included.

**Table 6. High-risk pathology of stage II colon cancer according to administration of oxaliplatin**

| Variable               | Without oxaliplatin (n = 194) | With oxaliplatin (n = 75) | P-value |
|------------------------|--------------------------------|--------------------------|---------|
| T4 lesion              | 26 (13.4)                      | 30 (40.0)                | <0.001  |
| Poorly differentiated   | 4 (2.1)                        | 7 (9.3)                  | 0.007   |
| Lymphatic invasion     | 67 (34.5)                      | 22 (29.3)                | 0.416   |
| Venous invasion        | 16 (8.2)                       | 8 (10.7)                 | 0.533   |
| Perineural invasion    | 81 (41.8)                      | 35 (46.7)                | 0.466   |
| Harvested LNs <12      | 3 (1.5)                        | 1 (1.3)                  | 0.897   |
| Bowel obstruction      | 61 (31.4)                      | 18 (24.0)                | 0.229   |
| Tumor perforation      | 29 (14.9)                      | 9 (12.0)                 | 0.534   |

Values are presented as number (%).

LNs, lymph nodes.
Our study results suggest that adjuvant chemotherapy using oral fluoropyrimidine monotherapy in patients with high-risk stage II colon cancer is beneficial with fewer severe adverse events but similar long-term survival outcomes compared to IV fluoropyrimidine-based chemotherapy.

Existing evidence on the effectiveness of adjuvant chemotherapy for patients with stage II colon cancer is not confirmative. Some studies reported better survival outcomes in the adjuvant chemotherapy group than in the observation group without oxaliplatin than in the group with oxaliplatin (16.5% vs. 69.3%, P < 0.001).

**DISCUSSION**

Adjuvant chemotherapy regimen for high-risk stage II colon cancer varies according to the administration route and the combination of therapeutic agents. While a conclusive randomized controlled trial has not been conducted, NCCN guidelines recommend adjuvant chemotherapy with drugs such as capecitabine, FL, FOLFOX, or capecitabine plus oxaliplatin as a treatment option for high-risk stage II colon cancer [7]. In our study, patients who received IV chemotherapy were younger but had more T4 lesions than those who received oral fluoropyrimidine monotherapy. Furthermore, oxaliplatin-treated patients were younger and had more T4 lesions, right-sided colon cancer, and poorly differentiated histology than those who did not receive this treatment. In general, patients with T4 lesions, right-sided colon cancer, poorly differentiated histology, and multiple high-risk features were expected to have poor survival outcomes; however, there was no difference in survival outcomes between the oral fluoropyrimidine monotherapy and IV chemotherapy groups. The multivariate analysis results were also comparable. According to the ESMO guidelines, T4 stage is considered a major prognostic parameter for risk assessment of stage II colon cancer [13]. Among the patients with T4 lesions in this study, more than half received oral fluoropyrimidine monotherapy. Furthermore, oxaliplatin-treated patients were younger and had more T4 lesions, right-sided colon cancer, and poorly differentiated histology than those who did not receive this treatment. In general, patients with T4 lesions, right-sided colon cancer, poorly differentiated histology, and multiple high-risk features were expected to have poor survival outcomes; however, there was no difference in survival outcomes between the oral fluoropyrimidine monotherapy and IV chemotherapy groups. The multivariate analysis results were also comparable. According to the ESMO guidelines, T4 stage is considered a major prognostic parameter for risk assessment of stage II colon cancer [13]. Among the patients with T4 lesions in this study, more than half received IV chemotherapy, including oxaliplatin. In other words, IV chemotherapy with oxaliplatin may improve survival outcomes in these patients. Future prospective research will be required.
to confirm our findings.

Most patients with cancer prefer oral chemotherapy to IV chemotherapy when the treatment efficacy is similar [11,21,22]. In previous studies, the use of oral capcitabine monotherapy as adjuvant or palliative treatment in stage III or metastatic colon cancer showed similar efficacy and fewer adverse events compared with IV 5-FU/leucovorin chemotherapy [12,14]. However, data on adjuvant oral fluoropyrimidine monotherapy for stage II colon cancer is insufficient. In this study, OS and DFS were not different between the oral fluoropyrimidine monotherapy and IV chemotherapy groups. The incidence of treatment-related adverse events was much less in the oral fluoropyrimidine monotherapy group than in the IV chemotherapy group (69.8% vs. 99.0%, P < 0.001). Only the hand-foot syndrome was more frequent in the oral fluoropyrimidine monotherapy group (45.9% vs. 4.1%, P < 0.001), which is consistent with previous studies [23,24]. Severe adverse events of grade ≥3 were almost 3-fold higher in the IV chemotherapy group than in the oral fluoropyrimidine monotherapy group (34.0% vs. 12.2%, P < 0.001). Adverse events trigger a reduction of the initially planned therapeutic dose of the chemotherapeutic agents. Moreover, uncontrolled or severe adverse events can lead to the early termination of adjuvant chemotherapy. In this study, adjuvant chemotherapy was completed with initially scheduled cycles in 90% of patients in both oral fluoropyrimidine monotherapy and IV chemotherapy groups. However, the number of dose reduction cases during the treatment period due to adverse events was 4-fold higher in the IV chemotherapy group than in the oral fluoropyrimidine monotherapy group (58.8% vs. 15.7%, P < 0.001). Consequently, patients who received oral fluoropyrimidine monotherapy had a lower risk of adverse events and dosage reduction than those who received the IV fluoropyrimidine-based chemotherapy.

The IV chemotherapy in this study mainly comprised oxaliplatin-containing regimen (75 of 97, 77.3%). The severity of oxaliplatin-induced peripheral neuropathy increases by the dosage and duration of oxaliplatin administration [8-10,25-27]. In this study, patients who did not receive oxaliplatin had fewer severe adverse events than those who did, but no difference in survival outcomes was observed. Our observations are generally consistent with the results of the MOSAIC study, in which there were no differences in DFS and OS outcomes in patients with high-risk stage II colon cancer between FOLFOX and FL (10-year DFS rate, 72.7% vs. 67.0% [hazard ratio, 0.79; 95% confidence interval, 0.55–1.13; P = 0.194] and 10-year OS rate, 75.4% vs. 71.7% [hazard ratio, 0.89; 95% confidence interval, 0.60–1.32; P = 0.579], respectively) [4]. This suggests that oral fluoropyrimidine monotherapy can be used preferentially for most patients with high-risk stage II colon cancer.

The limitations of this study are as follows. First, this was a retrospective, single-center study with small number of enrolled patients. Minor adverse events are sometimes overlooked because chemotherapy toxicity is often underestimated in outpatient clinics in the real world. Furthermore, a small sample size is insufficient to detect minor changes in survival following IV or oxaliplatin chemotherapy. In this study, no subgroup benefited more from oxaliplatin-containing combination therapy compared to fluoropyrimidine monotherapy. Therefore, we acknowledge that further well-designed prospective studies are warranted to generalize the result of our study to various populations and investigate whether there are patients with high-risk stage II colon cancer who can benefit more from oxaliplatin-containing combination therapy than from fluoropyrimidine monotherapy. Second, during the 12-year period (2003–2014) in which adjuvant chemotherapy was administered in this study, the Korean National Health Insurance coverage criteria were changed. In January 2006, FOLFOX and capcitabine monotherapy were added to the National Health Insurance as adjuvant chemotherapy for colon cancer, and this has consequently led to a significant decrease in the use of UFT and an increase in the number of patients receiving adjuvant FOLFOX or capcitabine monotherapy. Therefore, we cannot rule out the potential bias in our results due to the medical policy changes.

In conclusion, our study suggests that oral fluoropyrimidine monotherapy is an effective and convenient adjuvant treatment for patients with high-risk stage II colon cancer, with similar survival outcomes and fewer chemotherapy-related adverse events than IV fluoropyrimidine-based chemotherapy. Therefore, oral fluoropyrimidine monotherapy may be considered the preferential therapy for most patients with high-risk stage II colon cancer. Future prospective studies are needed to confirm our observations.

ACKNOWLEDGEMENTS

Fund/Grant Support
This work was supported by Hanmi Healthcare, Korea. The funding source had no role in the study design, implementation, data collection, analysis, and interpretation, or in the preparation, review, or approval of the manuscript.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

ORCID iD
Jung Rae Cho: https://orcid.org/0000-0003-4569-9479
Keun-Wook Lee: https://orcid.org/0000-0002-8491-703X
Heung-Kwon Oh: https://orcid.org/0000-0002-8066-2367
Jin Won Kim: https://orcid.org/0000-0002-1357-7015
Ji-Won Kim: https://orcid.org/0000-0001-6426-9074
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

2. Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat 2020;52:351-8.

3. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74.

4. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33:4176-87.

5. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 2010;17:959-66.

6. Quasar Collaborative Group: Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.

7. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology [Internet]. Plymouth Meeting (PA): NCCN; c2021 [cited 2021 Apr 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

8. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.

9. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204.

10. Raphael MJ, Fischer HD, Fung K, Austin PC, Anderson GM, Booth CM, et al. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 2017;16:397-404.

11. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58.

12. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capicitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.

13. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:301-305.

14. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75.

15. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.

16. Allegra CJ, Yothers G, O’Connell MJ, Shariat S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.

17. Punt CJ, Buyse M, Kühne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003.

18. Division of Cancer Treatment & Diagnosis. National Cancer Institute. Adverse events/CTCAE [Internet]. Bethesda (MD): National Institutes of Health; c2019 [cited 2019 Dec 12]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

19. Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ.
Hanna TP, et al. Adjuvant chemotherapy for stage II colon cancer: practice patterns and effectiveness in the general population. Clin Oncol (R Coll Radiol) 2017;29:e29-38.

20. Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, et al. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer: a EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. Eur J Cancer 2016;63:110-7.

21. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-7.

22. Schmoll HJ, Arnold D. Update on capecitabine in colorectal cancer. Oncologist 2006;11:1003-9.

23. Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 2004;44:1166-72.

24. Urakawa R, Tarutani M, Kubota K, Uejima E. Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer 2019;10:4846-51.

25. Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol 2019;5:1574-81.

26. Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J Clin Oncol 2019;37:1436-47.

27. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3953-60.